Perella Weinberg's Bob Steel talks about his history with Larry Fink, BlackRock's expansion into alternative assets, and why ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide ... including clinical ...

However, analysts expect the picture is set to shift over the next ... "Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial" was originally created and published by ...

Although Novo Nordisk and Eli Lilly are the main players in the GLP-1 arena, a number of other pharmaceutical companies are ...

Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in ...

(GIP is glucose-dependent insulinotropic polypeptide ... investors need to zoom out and think about the bigger picture. The reality is that Viking has a long road ahead. While its clinical ...

Good morning, everyone. Welcome to the Conference Call for Analysts and Investor for 2025 First Fiscal Quarter Results of Infineon. Today's call will be hosted by Alexander Foltin, Executive Vice ...

Hengrui has ongoing Phase III clinical trials for its GLP-1/GIP product in China ... However, analysts expect the picture is set to shift over the next decade, pointing to the 323 active GLP-1Rs ...

MCN: In the bigger picture, apart from Foresite ... The next wave were drugs targeting other receptors in the same family, like GIP. [Eli Lilly’s] Mounjaro is a next-generation drug.